A Multi-center, Open-label, Randomized, Controlled Phase I Trial to Investigate the Effects of Cilengitide (EMD 121974) Using Dynamic MR and FET-PET Imaging as a Pharmacodynamic Measure of Response in Subjects With Newly Diagnosed Glioblastoma

Trial Profile

A Multi-center, Open-label, Randomized, Controlled Phase I Trial to Investigate the Effects of Cilengitide (EMD 121974) Using Dynamic MR and FET-PET Imaging as a Pharmacodynamic Measure of Response in Subjects With Newly Diagnosed Glioblastoma

Discontinued
Phase of Trial: Phase I

Latest Information Update: 10 Apr 2013

At a glance

  • Drugs Cilengitide (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Pharmacodynamics
  • Most Recent Events

    • 01 Jan 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 01 Aug 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 26 Mar 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top